Multiple FDA User Fee Policies Complicate Combo Product Review Process
This article was originally published in The Gray Sheet
Executive Summary
Manufacturers of combination products should not be required to submit two separate filings to FDA, in part because of practical questions concerning user fee collection across the agency's centers, Wyeth Associate Director-Regulatory Affairs Owen Fields, PhD, said during FDA's public meeting on combination products Nov. 25